Corporate presentation outlines China commercial model and protein degrader pipeline
Gyre Therapeutics outlined a global development model anchored in China discovery and commercialization, paired with U.S.-led clinical advancement.
China commercial portfolio centered on ETUARY, the company’s market-leading pirfenidone brand for idiopathic pulmonary fibrosis.
FY26 ETUARY total revenue guidance set at $100.5 million-$111 million.
Hydronidone (F351) NDA filing accepted by China’s NMPA in May 2026; potential launch targeted for early 2027.
Pipeline priorities include targeted protein degraders and degrader-antibody conjugates, with initial IND submissions for select programs planned for Q1 2027.
GYRE•
